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Abstract 
Purpose of review: Vitamin D is essential for bone health, and may also have important functions in 
immunity and other systems. Vitamin D deficiency is common, and testing and supplementation is 
increasing.  Serum vitamin D is lower in obese people; it is important to understand the mechanism 
of this effect and whether it indicates clinically significant deficiency. 
Recent findings: Vitamin D is fat soluble, and distributed into fat, muscle, liver and serum. All of 
these compartments are increased in volume in obesity, so the lower vitamin D likely reflects a 
volumetric dilution effect and whole body stores of vitamin D may be adequate. Despite lower 
serum vitamin D, obese adults do not have higher bone turnover or lower bone mineral density 
(BMD). Patients undergoing bariatric surgery do have bone loss, and ensuring vitamin D sufficiency 
in these patients may help to attenuate bone loss. 
Summary: Lower vitamin D in obese people is a consistent finding across age, ethnicity and 
geography. This may not always reflect a clinical problem. Obese people need higher loading doses 
of vitamin D to achieve the same serum 25OHD as normal weight.  
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Introduction 
The main source of vitamin D in humans is production from the action of UVB light on cholesterol in 
skin. There is a small contribution from dietary sources such as oily fish and fortified foods. There are 
some geographical variations, for example in Scandinavia, dietary fish is a major source, and in the 
USA there is more food fortification. Vitamin D deficiency is very prevalent in the northern 
hemisphere; most of the UK population are vitamin D deficient in winter 1.  
There is ongoing debate about the fundamental principles of defining vitamin D deficiency. The most 
commonly used measure of vitamin D status is total 25-hydroxyvitamin D (25OHD) which captures 
25OHD3 and 25OHD2. 25OHD has a long serum half-life and is a technically easy measurement, but it 
has been proposed that free (non-protein-bound) 25OHD is a better measurement because it more 
closely reflects biologically available 25OHD status. There are variations in the sufficiency threshold 
recommended by different advisory bodies, with recommendations generally between 50 and 75 
nmol/l 2,3. 
Vitamin D is a pre- hormone. It is converted to the active hormone 1,25 dihydroxyvitamin D 
(1,25(OH)2D) by 25-hydroxylation in the liver and 1-hydroxylation in the kidney. The final step of 1-
hydroxylation is tightly regulated to prevent hypercalcaemia. 
The main circulating form of vitamin D is 25OHD. It is protein-bound in circulation (about 85% to 
vitamin D binding protein (VDBP), and about 15% to albumin). 25OHD is fat soluble, and distributed 
into fat, muscle and liver, with smaller amounts into other tissues. 25OHD is cleared by 24-
hydroxylation to 24,25(OH)2D or other inactive metabolites. 
Active vitamin D, 1,25(OH)2D is required for gut absorption of dietary calcium. Severe vitamin D 
deficiency causes osteomalacia in adults and in children. Less severe insufficiency causes increased 
bone turnover and is associated with increased fracture risk. Vitamin D deficiency has been 
associated with a wide range of other disorders, particularly auto-immune disorders and cancers, 
but a causative role in these conditions is not yet well established.  
Obesity is inversely correlated with serum 25OHD. This is a consistent finding in adults and children 
of different ethnicities in a range of geographic locations. This observation raises several questions: 
Is the low serum 25OHD a consequence or cause of obesity? What is the cause of low serum 25OHD 
in obesity? Does the low serum 25OHD in obesity have clinical consequences for bone or other 
systems? Do obese people need higher doses of vitamin D supplements? Does vitamin D 
supplementation in obesity ameliorate any of the metabolic consequences of obesity? What 
happens to vitamin D status when weight changes rapidly after weight loss surgery? 
 
Relationship between body weight and vitamin D 
Obese people have lower serum 25OHD than normal weight people, and serum 25OHD is inversely 
correlated with body weight, BMI and fat mass. This has been shown in adults and children in 
northern and southern Europe, Australia and New Zealand, Saudi Arabia, Latin America and in 
White, Black and Hispanic groups in the USA 4-12. Serum 25OHD is about 20% lower in obese people 
than normal weight 4,5,13, and the prevalence of 25OHD deficiency is greater in obese people, 
reported at between 40-80% 4,9,12. 
Other measures of vitamin D status (free 25OHD and 1,25(OH)2D) are also lower in obesity 4,14.  
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Parathyroid hormone is often used as an indicator of vitamin D status. PTH tends to be higher in 
obesity 15, but the relationship between serum calcium and PTH is left-shifted in obesity 16, so it is 
difficult to interpret the clinical significance of higher PTH.  
It is likely that low serum 25OHD is a consequence of obesity, rather than the cause of obesity. A 
large genetic study found that high BMI and genes that predispose to obesity decrease serum 
25OHD, while low 25OHD and genes associated with low 25OHD have very little effect on obesity17. 
In meta-analysis, vitamin D supplementation has no effect on body weight or fat mass18.  
 
Causes of low 25OHD in obesity 
There are a number of possible mechanisms that could cause low 25OHD in obesity. There could be 
lower input due to lower dietary intake, lower sunlight exposure or impaired skin synthesis of 
vitamin D. Alterations in protein binding or faster metabolic clearance in obesity could lead to lower 
serum 25OHD. Or the lower serum 25OHD could be due to distribution of 25OHD into a larger whole 
body tissue volume, particularly if 25OHD was actively sequestered in other tissues. 
 
Dietary vitamin D intake did not differ between obese and normal weight adults in a UK population 4. 
Obese people may have less sunlight exposure than normal weight people 19 in some geographic 
regions, although in two UK studies, sunlight exposure did not vary with BMI 4,20. When exposed to 
UVB, normal-weight and obese people have a similar cutaneous synthesis of vitamin D 21. Clearly, 
diet and sunlight behaviours will vary between different geographic and cultural groups, and may be 
a contributory factor to lower vitamin D in some groups. 
 
Serum VDBP and albumin concentrations affect the total 25OHD measurement, and there are 
genetic variations in VDBP which cause variation in the binding affinity of DBP. However, VDBP and 
albumin do not differ between obese and normal weight people, and the distribution of VDBP 
genotypes is similar in obese and normal weight groups 4,22.  
 
If metabolic clearance rate of 25OHD were faster in obesity, the half-life of 25OHD would be shorter 
and circulating 25OHD would be lower. Measurements using a stable isotope 25OHD tracer show 
that metabolic clearance is similar in obese and normal weight adults 4, so this is unlikely to be the 
explanation for lower serum 25OHD. 
 
The most important mechanism is probably volumetric dilution of 25OHD into greater tissue volume 
in obese people. 25OHD is distributed into serum, fat, muscle, liver and a small amount into other 
tissues 23, and all of these compartments are increased in obesity. The difference in serum 25OHD 
between obese and normal weight groups is greater in summer than in winter because the summer 
rise in serum 25OHD is less in obese people 4,24,25. Obese people get similar sunlight exposure to 
normal weight people, and produce the same amount of vitamin D in response to sunlight exposure, 
but the synthesised vitamin is distributed into a larger volume, so the amount distributed into serum 
is less.  There is a similar difference between obese and normal weight people in response to oral 
vitamin D dosing, with a smaller serum 25OHD rise in obesity 26. The dose-response relationship of 
vitamin D supplementation in obese adults is BMI-dependent and curvilinear, consistent with 
volumetric dilution 27 (Figure 1). The clinical implication of this volumetric dilution effect is that 
obese people will need larger loading doses of vitamin D than normal weight to achieve the same 
serum level of vitamin D, but on cessation of supplementation may have a slower decrease in serum 
vitamin D due to redistribution from other tissue stores. Conversely, people with low body weight 
would have a large rise in serum vitamin D after dosing (due to the smaller volume of distribution), 
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but would become deficient again quickly if supplementation was stopped (due to less tissue 
storage). 
It has been proposed that vitamin D is actively retained (sequestered) in fat but the modelling of the 
dose-ƌĞƐƉŽŶƐĞĚŽĞƐŶ ?ƚƐĞĞŵĐŽŶƐŝƐƚĞŶƚǁŝƚŚƚŚĂƚŚǇƉŽƚŚĞƐŝƐ ?dŚĞƌĞŝƐĞǆƉĞƌŝŵĞŶƚĂůĞǀŝĚĞŶĐĞƚŚĂƚ
vitamin D concentration in abdominal subcutaneous fat increases with vitamin D supplementation 
28,29, and one in vitro study suggests that adipocytes from insulin-resistant obese people might have 
impaired release of vitamin D 30. Adipocytes express 1-hydroxylase, but also 24-hydroxylase, so can 
activate and inactivate 25OHD. The activity of the enzymes may be altered in obesity, which could 
affect the amount of 25OHD available for release into serum 31. However the distribution and 
concentration of vitamin D and 25OHD in subcutaneous and omental fat does not differ between 
obese and normal weight people, and the correlation between 25OHD in subcutaneous fat and 
serum is similar in obese and normal weight 32.  
  
 
Does lower 25OHD have clinical consequences in obesity? 
Usually, low total 25OHD, free 25OHD and 1,25(OH)2D would lead to lower dietary calcium 
absorption, and increased bone turnover with lower bone mineral density (BMD). However, obese 
adults have lower bone turnover than normal weight, and higher BMD with thicker, denser cortices 
and greater trabecular number 33. It is important to note that in contrast, obesity in children has 
adverse effects on bone strength 34. 
This lack of adverse effects on bone may indicate that obese people are not truly vitamin D deficient; 
although serum 25OHD is lower due to volumetric dilution, their whole body vitamin D stores are 
greater due to the reservoir in their fat tissue, which maintains an equilibrium with serum 25OHD 
and a sufficient supply. 
An alternative explanation is that obese people are vitamin D deficient but that other effects of 
obesity compensate for the effects of vitamin D deficiency. For example, greater skeletal loading or 
the action of hormones such as leptin, adiponectin or oestrogen are known to have positive effects 
on bone mass.  
If obese people are truly vitamin D deficient, there may be implications for systems other than bone. 
Vitamin D deficiency has been associated with a large number of disorders, such as auto-immunity, 
cancer, neurodegenerative disease and metabolic syndrome. However, there is not yet clear 
evidence for a causative role of vitamin D deficiency in many of these conditions 35. Obesity does 
increase the risk for several of these disorders but there are other possible mechanisms than low 
vitamin D for these associations, and the interaction of vitamin D and obesity in causation has not 
yet been clearly characterised 36.  
In the US NHANES population study, low serum 25OHD was associated with higher all-cause 
mortality in postmenopausal women with normal waist circumference; the hazard ratio for the 
lowest versus the highest serum vitamin D quartile (< 36.5 nmol/l vs > 65.4 nmol/l) was 1.85 (95% CI 
1.00 to 3.44). In women with abdominal obesity there was no association between serum 25OHD 
quartile and all-cause mortality (HR 0.96, 95% CI 0.52 to 1.76) 37. This result suggests that obesity 
does modulate the relationship between serum vitamin D and health outcomes. 
 
Does vitamin D supplementation improve the adverse metabolic profile in obesity?  
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A recent meta-analysis found only four or five good quality intervention studies for each of the 
metabolic parameters they considered (fat mass, blood pressure, lipids and glucose tolerance). 
There were some positive effects of vitamin D supplementation on fat mass, triglycerides, HDL 
cholesterol and oral glucose tolerance, but adverse effects on LDL cholesterol and blood pressure. 
However, due to the small numbers of studies and significant heterogeneity of methodology, the 
current evidence is insufficient to draw conclusions 38. 
Inflammatory markers do not seem to be higher in vitamin D deficient obese people than in vitamin 
D replete obese people 39 and vitamin D supplementation has little effect on circulating 
inflammatory markers in overweight or obese people 40-42. 
 
Vitamin D with weight loss surgery 
Obesity surgery leads to substantial weight loss in most patients, often about 30% of their body 
weight. The two main types of surgery are gastric volume reduction (e.g. sleeve gastrectomy) or 
malabsorptive (most commonly Roux-en-Y gastric bypass (RYGB), and less commonly biliopancreatic 
diversion with gastric switch). As expected, obese people have low serum 25OHD pre-operatively. 
Most studies find that serum 25OHD increases in the first month after surgery 43, which may reflect 
the smaller volume of dilution with weight loss. One study tried to determine whether the vitamin D 
stored in fat was mobilised into serum during weight loss, but found no association between vitamin 
D concentration in fat at time of surgery and subsequent change in serum 25OHD 44. With 
biliopancreatic diversion, serum 25OHD tends to decline immediately after surgery, which is 
probably due to the greater bile and fat malabsorption with this procedure 45. 
In the longer term, vitamin D decreases. Five years after RYGB, with calcium and vitamin D 
supplementation in most patients, they are just vitamin D sufficient at about 50 nmol/l, but have 
parathyroid hormone above the reference range 46.  Bone density and microarchitecture 
deteriorates for at least two years after RYGB, beyond stabilisation of body weight, despite vitamin D 
supplementation which maintained serum 25OHD well into the replete range 47. The bone loss is 
likely to be multifactorial, with decreased loading, changes in adipokines, gut hormones, insulin and 
sex hormones as well as other nutritional factors. Maintaining vitamin D sufficiency after bariatric 
surgery may require higher doses than standard supplementation, but in combination with calcium 
and protein supplements and physical activity may attenuate bone loss 48. 
 
Optimum vitamin D dosing for BMI 
As explained above, the observed serum 25OHD of about 20% below the normal weight population 
in obese people may not indicate true deficiency or a clinical problem. However, despite higher total 
body stores, obese people can become vitamin D deficient for the same reasons as any other group. 
If obese people are treated to the same serum 25OHD repletion threshold as normal weight, higher 
loading doses will be required due the greater volume of distribution. Obese people may need 
repeated loading courses to achieve repletion. (Conversely, people with below-normal BMI may 
need lower doses, but more frequently). Drincic 27 describes the formula to calculate the required 
vitamin D dose based on BMI and the required increment in serum 25OHD. Because there are no 
alterations in protein binding or metabolic clearance rate in obesity, maintenance dose 
requirements should be similar to normal weight (although as above, higher doses may be need 
after bariatric surgery). 
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Summary 
Obesity is associated with lower serum vitamin D, assessed as total 25OHD, free 25OHD or 
1,25(OH)2D. This is likely due to volumetric dilution into the greater volumes of serum, fat, muscle 
and liver. The observed lower serum ǀŝƚĂŵŝŶŝŶŽďĞƐŝƚǇĚŽĞƐŶ ?ƚƐĞĞŵƚŽ have adverse 
consequences for bone health. There is less available information about consequences for other 
systems, and but no clear evidence of adverse effects. Vvitamin D supplementation has not yet been 
clearly shown to benefit the adverse metabolic profile in obesity. More information on other system 
effects is needed before it can be determined what the serum 25OHD target for repletion should be 
in obese people. Vitamin D does decrease after bariatric surgery, and careful attention to vitamin D 
repletion might help to prevent bone loss in these patients. Obese people will need greater loading 
doses of vitamin D to achieve the same serum 25OHD threshold as normal weight.Obese people will 
need higher loading doses than normal weight to achieve the same serum level of vitamin D, but because 
the metabolic clearance rate is not affected by obesity, the maintenance dose should be the similar. 
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Key points 
Serum vitamin D is low in obese people across age, ethnicity and geography. 
The low vitamin D is due to greater volumetric dilution, and may not necessarily indicate vitamin D 
deficiency. 
Despite lower serum vitamin D, obese people have lower bone turnover and higher bone density 
than normal weight people. 
Bariatric surgery does cause bone loss, and vitamin D supplementation may be important in this 
group of patients. 
Obese people need higher loading doses of vitamin D than normal weight people to achieve a similar 
increment in serum vitamin D. 
 
Figure legend 
Figure 1 Serum response to oral vitamin D supplementation is BMI- and dose-dependent.  
The time course of the 25(OH)D increment in the obese 1,000-/hŐƌŽƵƉ ?ӑ ? ?ƚŚĞobese 5,000-IU 
group (?), and the obese 10,000-IU group (ප) in the current study, contrasted with a historical 
comparison from normal-weight males who were taking 5,000 IU (?) daily and 10,000 IU (Ŷ) daily. 
The error bars are 1 SEM. 
Reproduced with permission from Drincic et al, J Clin Endocrinol Metab 2013;98(12):4845-4851 
 
